What ABLi Therapeutics does

ABLi Therapeutics is a clinical-stage biotechnology company developing small-molecule c-Abl (Abelson Tyrosine Kinase) inhibitors as disease-modifying therapies for neurodegenerative diseases, with an initial focus on Parkinson's disease and related synucleinopathies including Multiple System Atrophy (MSA) and Dementia with Lewy Body (DLB). The company's lead candidate, risvodetinib (ABLi-148009), is an oral once-daily selective c-Abl kinase inhibitor that targets both neurodegenerative cell death and neuroinflammatory pathways; human exposure is reported at 2-fold to 200-fold higher than any currently approved c-Abl inhibitor. Compounds are designed using the proprietary RAMP™ (Re-engineering Approach with Metabolism Preserved) drug innovation engine, which leverages clinically validated kinase inhibitor data to optimize brain penetration, potency, and safety.

The company's pipeline is anchored by the completed Phase 2 '201 Trial' in 120 untreated Parkinson's disease patients across 32 US sites, which demonstrated the first treatment-dependent reduction in alpha-synuclein pathology in a randomized, placebo-controlled study (published in Nature Aging, February 2026). Planned registrational work includes the ~450-participant Phase 3 CAMPD trial in untreated PD, a Phase 2/3 '202 Trial' for MSA across up to 35 EU and US sites, a 12-month open-label 303 extension, and inclusion in the Michael J. Fox Foundation's Path to Prevention platform trial for prodromal PD. ABLi has built a translational ecosystem around SynuSight Biotech (FD4 alpha-synuclein PET tracer), XingImaging (PET manufacturing and clinical imaging), CND Life Sciences (Syn-One biomarker services with AI-assisted NerValence digital pathology co-developed with Visiopharm), and MJFF.

ABLi is pre-revenue and incorporated in Delaware, headquartered in Atlanta, Georgia, with 11-50 employees. The business model is licensing/royalty-oriented in the long term, but near-term monetization will be driven by advancing risvodetinib through regulatory approval for commercial launch via traditional pharmaceutical wholesale and specialty pharmacy distribution. Capital formation to date consists of a $1,000,000 exempt equity offering under SEC Rule 506(b) (first sales September 15, 2025) to 10 undisclosed investors, with no institutional venture capital lead disclosed in available materials.

Name

ABLi Therapeutics

Legal name

ABLi Therapeutics, Inc.

Website

https://ablitherapeutics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

ABLi Therapeutics is a clinical-stage biotechnology company developing oral small-molecule c-Abl kinase inhibitors, led by risvodetinib, as disease-modifying therapies for Parkinson's disease, Multiple System Atrophy, and Dementia with Lewy Body.

Ownership category

akta.pro rank

Product category

Neurodegenerative Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

akta.pro secondary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• Small molecule therapeutics
• Kinase inhibitors
• Neurodegenerative disease treatment
• Parkinson's disease therapy
• Central nervous system drugs

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pre-commercial / Pipeline Revenue: ABLi is a pre-revenue clinical-stage biotechnology company developing risvodetinib and a portfolio of second-generation c-Abl inhibitors. The company filed a $1,000,000 exempt equity offering under Rule 506(b) with first sales beginning September 15, 2025. No commercialized products or approved therapies exist yet.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels9 records

Core offering

ABLi Therapeutics develops once-daily oral small-molecule inhibitors of c-Abl (Abelson Tyrosine) kinases for the treatment of neurodegenerative diseases. Its lead product candidate, risvodetinib (ABLi-148009), is being advanced as a disease-modifying therapy for Parkinson's disease, Multiple System Atrophy, and Dementia with Lewy Body, designed to halt both neurodegenerative cell death pathways and neuroinflammatory pathways. Discovery and lead optimization are powered by the proprietary RAMP™ drug innovation engine.

Product overview

ABLi Therapeutics is a biotechnology company developing a portfolio of small molecule therapeutics targeting Abelson Tyrosine Kinases (c-Abl kinases) for neurodegenerative diseases. The core product is Risvodetinib (ABLi-148009), an oral once-daily selective c-Abl kinase inhibitor being developed as a disease-modifying therapy for Parkinson's disease and related disorders including Multiple System Atrophy and Dementia with Lewy Body. The company's proprietary RAMP™ drug innovation engine facilitates the development of selective c-Abl inhibitors with enhanced brain penetration. The pipeline includes multiple clinical programs: the completed Phase 2 201 Trial demonstrating safety and first treatment-dependent reduction in alpha-synuclein pathology; planned Phase 3 trials including the CAMPD trial for Parkinson's disease, 202 Trial for MSA, and 303 open-label extension study. Risvodetinib has intellectual property protection beyond 2036.

Differentiator

Problem solved

Functional benefit

Brands

• RAMP™: Re-engineering Approach with Metabolism Preserved (RAMP™) - A proprietary drug innovation engine that utilizes clinically validated data of kinase inhibitors to design and develop novel product candidates with enhanced penetration into the brain, with potentially higher potency and improved safety to treat diseases in which kinase activation is implicated.

Products and services

• Risvodetinib (ABLi-148009) A potent, selective small-molecule inhibitor of non-receptor c-Abl kinases designed for once-daily oral use. Risvodetinib targets the underlying biological mechanisms driving Parkinson's disease initiation and progression by blocking both neurodegenerative cell death pathways and neurodegenerative inflammatory pathways, with human exposure 2-fold to 200-fold higher than any c-Abl inhibitor currently approved for human use. It is being developed as a disease-modifying therapy for Parkinson's disease, Multiple System Atrophy, and Dementia with Lewy Body.

Quantifiable outcome

• Risvodetinib demonstrated the first treatment-dependent reduction in alpha-synuclein pathology in a randomized, placebo-controlled Phase 2 trial (201 Trial, NCT05424276)
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core.

• The Michael J. Fox Foundation for Parkinson's Research (MJFF)coreStrategic or Co-development Partner · 27 January 2026ABLi entered a collaboration agreement with MJFF to include risvodetinib in the Path to Prevention (P2P) platform trial, a multi-arm, randomized, double-blind, placebo-controlled Phase 2 trial built on the PPMI study. The trial will investigate risvodetinib's safety and efficacy in prodromal Parkinson's disease participants with biomarker characteristics but not yet a formal diagnosis. ABLi is the first company to join the P2P platform. The collaboration aims to evaluate whether risvodetinib can prevent progression to a formal PD diagnosis.
• SynuSight BiotechcoreTechnology or Integration · 5 January 2026Non-exclusive clinical use license agreement permitting ABLi to utilize 18F-FD4 PET tracer in trials to evaluate risvodetinib as a disease-modifying therapy for Parkinson's disease. SynuSight pioneered the development of the alpha-synuclein aggregate-specific PET tracer FD4 to visualize alpha-synuclein pathology in human brain. SynuSight receives an upfront payment and subsequent license-related fees. ABLi plans to implement FD4 in two clinical trials in 2026 (ABILITY-PD and CAMPD).
• XingImagingcoreTechnology or Integration · 5 January 2026XingImaging is the U.S.-based manufacturer of 18F-FD4 and provides clinical imaging services. XingImaging married FD4 to the NeuroEXPLORER, a next-generation dedicated brain PET imager housed at Xing's facility in New Haven, CT. Xing provides services across the pre-clinical and clinical spectrum including radioligand development and manufacturing, design and implementation of clinical trials, and customized clinical imaging site coordination in multi-site imaging studies.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/abli-therapeutics
• Xx.com/ABLi_Thera
• Facebookfacebook.com/ABLiTherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ABLi Therapeutics